I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated below and is addressed to "Commissioner for Patents, Washington, DC 20231."

Atty Dkt No. 7500-0004.10 **PATENT**



"Express Mail" Mailing Label No.: EL 910 311 302 US Date of Deposit: February 7, 2002 Sam Pen Printed Name of Person Mailing Paper or Fee Signature of Person Mailing Paper or Fee

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

John M. PEZZUTO et al.

Divisional of Serial No.: 09/430,337

Group Art Unit: Unassigned

Filing Date: Concurrently herewith

Examiner: Unassigned

Title: PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHODS OF **USE THEREOF**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, DC 20231

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

The references identified below were disclosed and/or cited in parent application Serial No. 09/430,337, filed October 29, 1999, which is a continuation-in-part of application Serial No. 09/005/114, filed January 9, 1998, and, as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

PTO-1449 forms listing the references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the forms to indicate that the references have been reviewed and made of record. The references are as follows:

Patent No.	U.S. PATENT DOCUMENTS	
	Issue Date	Patentee
5,411,986	5/95	Cho et al.
5,747,536	5/98	T
6,008,260		Cavazza
6,080,701	12/99	Pezzuto et al.
	6/00	Jeandet et al.
6,132,740	10/00	Hu

	FOREIGN PATENT DOCUMENTS	
Document No.	Publication Date	Country
JP 409328410A	12/97	Japan
JP 61060609 (abstract only)	3/28/86	Japan
JP 10045566 (abstract only)	2/17/98	Japan
WO 99/04747	2/4/99	PCT

OTHER DOCUMENTS

Bertram (1979), "Reduction in the formation of carcinogen-induced transformed foci by penicillin G sodium in the C3H/10T.sub.1/2 CL8 cell line," Cancer Lett. 7:289-298;

Gerhauser et al. (1995), "Retinoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase," Nature Med. 1(3)260-266;

Goodwin (1984), "Immunologic effects of nonsteroidal anti-inflammatory drugs," Am. J. Med. 77:7-15;

Jang et al. (1997) Science 275(5297):218-220 (Abstract Only);

Jang et al. (1998), "Effects of Resveratrol on 12-O-Tetradecanoylphorbol-13-Acetate-Induced Oxidative Events and Gene Expression in Mouse Skin," Cancer Letters 134:81-89.

Jayatilake et al. (1993), "Kinase inhibitors from polygonum cuspidatum," J. Nat. Prod. 56(10):1805-1810;

Kulmacz et al., "Cyclo-oxygenase: measurement, purification and properties," pp. 209-277, in Prostaglandins and Related Substances, IRL Press, Oxford (1987);

Landolph, "Chemical transformation in C3H 10T1/2 C18 mouse embryo fibroblasts: historical background, assessment of the transformation assay, and evolution and optimization of the transformation assay protocol," pp. 185-199, in Transformation Assay of Established Cell Lines, T. Kakunaga et al., eds., Oxford Univ. Press, Toronto

Mannilla et al. (1993), "Anti-leukaemic compounds derived from stilbenes in Picea abies bark," Phytochemistry

Miura et al. (1997) Igaku no Ayumi 183(8):530-536 (Abstract Only);

Mondal et al. (1976), "Two-stage chemical oncogenesis in cultures of C3H/10T1/2 cells," Cancer Res. 36:2254-2260;

Moon et al., "Retinoid inhibition of experimental carcinogenesis," Chemistry and Biology of Retinoids, M.I. Dawson et al., eds., CRC Press, Boca Raton, FL, 501-518, 1990;

Plescia et al. (1975), "Subversion of immune system by tumor cells and role of prostaglandins," Proc. Nat. Acad. Sci., USA 72(5):1848-1851;

Prochaska et al. (1998), "Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers," Anal. Biochem. 169:328-336;

Reznikoff et al. (1973), "Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division," Cancer Res. 33:3239-3249;

Sanders et al. (1997), Book of Abstracts, 214th ACS National Meeting, Am. Chem. Soc., Sep. 7, 1997;

Shamon et al. (1994), "A correlative approach for the identification of antimutagens that demonstrate chemopreventive activity," Anticancer Res. 14:1775-1778;

Sharma et al. (1994), "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis," Cancer Res. 54:5848-5855;

Slowing et al. (1994), "Anti-inflammatory activity of leaf extracts of Eugenia jambos in rats," J. of Ethnopharmacol.

Sporn et al. (1979), "Chemoprevention of cancer with retinoids," Federation Proceedings 38(11):2528-2534; Subbaramaiah et al. (1998), "Resveratrol Inhibits the Expression of Cyclooxygenase-2 in Human Mammary and Oral Epithelial Cells," Pharmaceutical Biology 36:35-43.

Suh et al. (1995), "Discovery of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model," Anticancer Res. 15:233-240;

van der Ouderaa et al. (1982), "Purification of PGH synthase from sheep vesicular glands," Methods Enzymol.

OTHER DOCUMENTS

Wattenberg (1993), "Prevention-therapy-basic science and the resolution of the cancer problem: presidential address," *Cancer Research* 53:5890-5896;

Wild et al. (1987), "Prostaglandin H synthase-dependent mutagenic activation of heterocyclic aromatic amines of the IQ-type," *Carcinogenesis* 8(4):541-545;

Zenser et al. (1983), "Prostaglandin H synthase-catalyzed activation of benzidine: a model to assess pharmacologic intervention of the initiation of chemical carcinogenesis," *J. Pharmcol. Exp. Ther.* 227(3):545-550; and

Zhang et al. (1994), "Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates," *Proc. Natl. Acad. Sci., USA* 91:3147-3150.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As this Information Disclosure Statement is being filed concurrently with the application, no fee is required.

Respectfully submitted,

Date /

By:

JElin Hartrum

Registration No. 43,663

REED & ASSOCIATES 800 Menlo Avenue, Suite 210 Menlo Park, California 94025 (605) 330-0900 Telephone

(650) 330-0900 Telephone (650) 330-0980 Facsimile